FOXO4-DRI

Quick Facts

Introduction

FOXO4-DRI is a synthetic peptide engineered as a research tool to target cellular senescence — the state in which damaged cells stop dividing but resist dying, accumulating with age and secreting inflammatory factors. It is one of the most-discussed senolytic candidates in the longevity literature because, unlike broad metabolic interventions, it was rationally designed to interrupt a specific protein–protein interaction that keeps senescent cells alive. Within this library it is grouped with other longevity compounds such as Epitalon and the metabolic cofactor NAD+, though its mechanism is entirely distinct.

The concept behind FOXO4-DRI emerged from work showing that senescent cells depend on the transcription factor FOXO4 to sequester p53 in the nucleus, preventing p53 from initiating programmed cell death. By blocking that interaction, the peptide is studied as a way to selectively push senescent cells toward apoptosis while sparing healthy, dividing cells — the defining goal of senolytic research.

This profile covers what FOXO4-DRI is, its unusual D-retro-inverso design, the FOXO4–p53 mechanism, the senolytic research it appears in, and how it compares with other longevity approaches. Related entries are catalogued in the peptide database.

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide modeled on the region of FOXO4 that binds p53. The 'DRI' stands for D-retro-inverso — a peptide-engineering strategy in which the amino-acid sequence is reversed and each residue is built from a D-amino acid rather than the natural L form. The result is a molecule that presents a similar arrangement of side chains to its target but is far more resistant to the proteases that would rapidly degrade an ordinary peptide.

This design choice is what makes FOXO4-DRI notable as a research compound. A conventional peptide spanning the FOXO4 binding interface would be cleaved quickly in biological systems; the retro-inverso modification was introduced specifically to give the molecule enough stability to act as an interfering peptide. It is therefore studied as a decoy that competes with native FOXO4 for p53 binding.

Molecular and structural characteristics

The structural hallmark of FOXO4-DRI is its D-retro-inverso architecture. In a retro-inverso peptide, reversing the sequence and switching to D-amino acids produces a topology in which the side-chain positions approximate those of the original L-peptide while the backbone direction is inverted. This is a well-established medicinal-chemistry tactic for building protease-resistant mimics of protein-binding motifs.

Research preparations often append a cell-penetrating element so the relatively large peptide can reach its intracellular target, since FOXO4 and p53 operate inside the nucleus. Because exact constructs and lengths differ between sources, reported molecular weights and formulas vary; the functionally important feature is the preserved p53-binding interface rather than a single fixed mass.

Mechanism of action

In senescent cells, the transcription factor FOXO4 is upregulated and binds p53, holding it in the nucleus and preventing p53 from translocating to mitochondria to initiate apoptosis. This sequestration is part of how senescent cells maintain a kind of stalemate — they cannot divide, but they also avoid the cell-death program that would normally remove damaged cells.

FOXO4-DRI is designed to act as a competitive decoy: by occupying the FOXO4 interface, it interferes with the FOXO4–p53 complex, freeing p53. The released p53 can then drive apoptosis preferentially in senescent cells, which are the cells most dependent on this interaction for survival. Healthy cells, less reliant on FOXO4-mediated p53 sequestration, are studied as being comparatively unaffected — the basis for the proposed selectivity of the approach.

This targeted mechanism distinguishes FOXO4-DRI from longevity strategies that work on metabolism or signaling, such as boosting NAD+ or the pineal-peptide effects studied with Epitalon. Instead of slowing aging-related decline broadly, it is studied as a way to remove the senescent cells thought to contribute to that decline.

• Competes with native FOXO4 for binding to p53.
• Disrupts nuclear sequestration of p53 in senescent cells.
• Associated with p53-driven apoptosis selectively in senescent cells.
• D-retro-inverso design intended to resist proteolytic degradation.

Senolytic and cellular-senescence research

FOXO4-DRI rose to prominence through a foundational study in which the peptide was associated with reduced markers of senescence and improvements in several aging-related readouts in mouse models, including in naturally aged and progeroid animals. Investigators reported effects on fitness, fur density, and renal-function markers, framing the peptide as a proof-of-concept that targeted senescent-cell clearance could influence aging phenotypes.

Senescent cells are studied as drivers of the senescence-associated secretory phenotype (SASP) — a pro-inflammatory output that can propagate dysfunction to neighboring tissue. The research rationale for senolytics like FOXO4-DRI is that periodically eliminating these cells could reduce that inflammatory burden, which is why the compound is examined alongside broader longevity research on inflammation and tissue maintenance.

Comparison: FOXO4-DRI vs other longevity approaches

FOXO4-DRI is best understood by contrasting it with longevity compounds that act through different strategies. Epitalon is studied for telomerase and pineal effects, and NAD+ for metabolic and sirtuin signaling — neither is a senolytic. FOXO4-DRI is unique among them in being designed to clear senescent cells rather than to modulate aging-related metabolism.

Researchers comparing senolytic and metabolic longevity strategies often examine FOXO4-DRI alongside NAD+ and Epitalon. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

The D-retro-inverso design directly shapes FOXO4-DRI's pharmacokinetics. Because D-amino acids are not recognized by most proteases, the peptide is expected to resist enzymatic degradation far better than an equivalent L-peptide, supporting a longer functional presence in research settings. This stability is the entire point of the retro-inverso strategy.

A second consideration is intracellular delivery: because the FOXO4–p53 interaction occurs in the nucleus, the peptide must cross the cell membrane to act, which is why research constructs often incorporate cell-penetrating motifs. Reported animal studies used intermittent administration schedules consistent with the senolytic 'hit-and-run' concept — clearing senescent cells periodically rather than maintaining continuous exposure.

Reconstitution and handling considerations

Lyophilized FOXO4-DRI is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. Given the peptide's length and amino-acid composition, some preparations dissolve more readily with a small fraction of an appropriate co-solvent; the reconstituted solution should be clear, and cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is fully dissolved and clear before use.
• Some preparations may need a small co-solvent fraction to dissolve.
• Protect from light and avoid repeated freeze–thaw cycles.

Storage considerations

Lyophilized FOXO4-DRI is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting before freezing reduces how often a given solution is freeze–thaw cycled, which helps preserve the peptide's integrity.

Research limitations

FOXO4-DRI is an early-stage research compound. Its most cited findings come from mouse models, and there is little to no human data; senolytic biology as a whole is still emerging, and selectivity, optimal scheduling, and long-term safety remain open research questions. Because p53 is central to both apoptosis and tumor suppression, manipulating its regulation is studied carefully. It is described here strictly for research reference.

• Key evidence is from animal models, primarily mice.
• Human data are lacking; senolytic biology is still emerging.
• Selectivity, scheduling, and long-term safety are open questions.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017.Source
2. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020.Source
3. Di Micco R, et al. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat Rev Mol Cell Biol. 2021.Source